Welcome to LookChem.com Sign In|Join Free

CAS

  • or

132682-98-5

132682-98-5

Post Buying Request

132682-98-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

132682-98-5 Usage

Uses

Glufosfamide is an alkylating cytotoxic agent with increased antitumor selectivity and active transmembrane transport mechanism, that belongs to the oxazaphosphorine class. It is an attractive new agent for cancer therapy in humans.

Check Digit Verification of cas no

The CAS Registry Mumber 132682-98-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,6,8 and 2 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 132682-98:
(8*1)+(7*3)+(6*2)+(5*6)+(4*8)+(3*2)+(2*9)+(1*8)=135
135 % 10 = 5
So 132682-98-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1

132682-98-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol

1.2 Other means of identification

Product number -
Other names Glucosyl-ifosfamide mustard

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:132682-98-5 SDS

132682-98-5Synthetic route

C18H29Cl2N2O11P
132683-11-5

C18H29Cl2N2O11P

glufosfamide
132682-98-5

glufosfamide

Conditions
ConditionsYield
Stage #1: C18H29Cl2N2O11P With methanol; sodium methylate at 0 - 20℃; for 0.5h;
Stage #2:		89%
glufosfamide
132682-98-5

glufosfamide

A

ifosfamide mustard
31645-39-3

ifosfamide mustard

B

N-(2-chloroethyl)-N'-(aziridinyl) ifosfamide mustard

N-(2-chloroethyl)-N'-(aziridinyl) ifosfamide mustard

C

C4H12ClN2O3P

C4H12ClN2O3P

D

dihydroxyIPM

dihydroxyIPM

Conditions
ConditionsYield
With cacodylate buffer at 37℃; pH=7.4; Product distribution;
acetic anhydride
108-24-7

acetic anhydride

glufosfamide
132682-98-5

glufosfamide

C18H29Cl2N2O11P
132683-11-5

C18H29Cl2N2O11P

Conditions
ConditionsYield
With pyridine at 20℃; for 1h; Product distribution / selectivity;

132682-98-5Upstream product

132682-98-5Downstream Products

132682-98-5Related news

Glufosfamide (cas 132682-98-5) administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group☆08/28/2019

The activity of glufosfamide (β-d-glucopyranosyl-N,N′-di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. Chemotherapy-naı̈ve patients with advanced or metastatic disease were treated with glufosfamide (5 g/m2) using...detailed

Glufosfamide (cas 132682-98-5) administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC-New Drug Development Group☆08/27/2019

The activity of glufosfamide (β-d-glucosylisophosphoramide mustard) was tested in a multicentre phase II clinical trial in patients with advanced non-small cell lung cancer (NSCLC) who had received one prior line of platinum-based chemotherapy. Patients were treated with 5000 mg/m2 glufosfamide...detailed

Molecular and Cellular PharmacologyPossible contribution of β-glucosidase and caspases in the cytotoxicity of Glufosfamide (cas 132682-98-5) in colon cancer cells08/26/2019

Glycoconjugates represent a recent trend in cancer chemotherapy that adopts the concept of selective prodrug/drug targeting of tumor cells by binding to specific transmembrane glucose transporters. Following preferential uptake of sugar conjugates into cancer cells, they are presumably subject t...detailed

A randomised Phase III trial of Glufosfamide (cas 132682-98-5) compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine☆08/24/2019

PurposeThere are currently no approved therapies for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine. This Phase III trial evaluated the efficacy and safety of glufosfamide as compared with best supportive care (BSC) in this patient population.detailed

Stability of Glufosfamide (cas 132682-98-5) in phosphate buffers and in biological samples08/23/2019

Glufosfamide is a new, potential chemotherapeutic agent currently under investigation. Stability of glufosfamide was investigated in sodium phosphate buffers with different pH and temperature and in biological samples. Glufosfamide and isophosphamide mustard were quantified simultaneously using ...detailed

132682-98-5Relevant articles and documents

GLYCOCONJUGATES OF PHOSPHORAMIDATE ALKYLATORS FOR TREATMENT OF CANCER

-

Page/Page column 35, (2010/11/29)

Bromoglufosfamide and related compounds are useful in the treatment of cancer and other hyperproliferative diseases. Glufosfamide and bromoglufosfamide are synthesized by reacting the corresponding tetracetyl derivatives with MeOH and a catalytic amount of MeO(-). Tetraacetyl glufosfamide is obtained by reacting a tetraacetyl trichloroacetamidate intermediate of glucose, ifosfamide mustard, and an acid in an anhydrous polar solvent.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 132682-98-5